Promising Results for Chemo-Free Immunotherapy in Early-Stage Triple-Negative Breast Cancer
Phase 2 trial shows potential for immunotherapy without chemo in early TNBC, especially with high TILs.
Latest (Page 4)
Doxorubicin Addition to Sorafenib Fails to Improve Survival in Advanced Liver Cancer
Phase III trial shows doxorubicin plus sorafenib no better than sorafenib alone for advanced HCC.
Lower Dose Olanzapine: A Game-Changer for Chemo Nausea Prevention
Study finds lower olanzapine dose equally effective for chemo-induced nausea with less drowsiness.
Long-Term Study Challenges Rituximab Maintenance in Low-Burden Follicular Lymphoma
Extended follow-up of RESORT trial shows rituximab retreatment may be preferable to maintenance therapy.
Combo Therapy Shows Promise in Advanced Endometrial Cancer Trial
Phase 2 trial evaluates PARP inhibitor and antiangiogenic agent in recurrent endometrial cancer.
Acyclovir Prophylaxis Slashes Mucositis Risk in Stem Cell Transplant Patients
Study shows acyclovir prophylaxis significantly reduces oral mucositis in autologous stem cell transplants.
Sintilimab Boosts Survival in Advanced Gastric Cancer: ORIENT-16 Trial Results
Immunotherapy drug sintilimab improves survival in advanced gastric cancer when added to chemotherapy.
Immunotherapy Breakthrough: Toripalimab Boosts Survival in Nasopharyngeal Cancer
Toripalimab plus chemotherapy significantly improves survival in recurrent/metastatic nasopharyngeal carcinoma.
New Strategies Explored: Immune Checkpoint Inhibitors in Ovarian Cancer
Study compares sequential vs. combination immunotherapy in platinum-resistant ovarian cancer patients.
Ripretinib Shows Promise in Chinese GIST Patients: Efficacy and Safety Comparable to Sunitinib
Phase 2 trial finds ripretinib effective and safer than sunitinib for advanced GIST in Chinese patients.
Pembrolizumab Boosts Early TNBC Outcomes in Asian Patients: KEYNOTE-522 Subanalysis
Immunotherapy improves pathological complete response and event-free survival in Asian TNBC patients.
New Hope in Lung Cancer: Dostarlimab Rivals Pembrolizumab in First-Line Treatment
Phase II trial shows dostarlimab plus chemo matches pembrolizumab efficacy for metastatic NSCLC patients.
Novel Oral SERD Shows Promise in Early-Stage Breast Cancer Study
Amcenestrant demonstrates antiproliferative effects and ER degradation in ER+/HER2- breast cancer patients.